glp-1 coverage news CMS Extends Medicare's Short-Term Bridge Program for Obesity Drug A Bridge to Nowhere? Medicare's
Description
Coverage of GLP-1 weight-loss drugs is growing among the largest employers (5000+ workers), now at 43%
Constipation occurs in
They are primarily used in the management of type 2 diabetes (T2D).
Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand
Find which approach fits your specific goals.
